Please login to the form below

Not currently logged in
Email:
Password:

Cellectis appoints Dr Loan Hoang-Sayag as chief medical officer

She joins the biopharma company from Quintiles

New York-based Cellectis has appointed Dr Loan Hoang-Sayag at its chief medical officer.

She will be responsible for bringing Cellectis' product candidates into clinical stage development as well as strategic and operational management of the company's therapeutic activities.

Dr Hoang-Sayag joins Cellectis after 10 years at Quintiles where she most recently held the role of senior director of medical science.

She has over 20 years of experience in haematology and medical oncology, and prior to Quintiles held positions at Pierre Fabre Oncology and Hoffman La Roche.

Dr André Choulika, chairman and chief executive officer of Cellectis, said: “Dr Hoang-Sayag's experience in oncology clinical development - specifically in strategy and delivery in all phases in the pharmaceutical, biotechnology and clinical research spaces - enables her to lead Cellectis' strategy and generate awareness around the breakthrough work that we are doing as a leader and innovator in the field.”

Dr Hoang-Sayag will report directly to executive vice president and chief operating officer, Mathieu Simon.

Simon said: “Dr Hoang-Sayag's impressive and extensive professional background makes her a perfect fit for the Cellectis team, as her clinical development expertise will play a key role in helping us to achieve our goals and strategic priorities in 2016 and beyond.”

12th January 2016

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics